Development of patient derived xenografts (PDXs) for lung cancer.

• Research type

  Research Study

• Full title

  PAtient DeriveD xenografts (PDXs) in mice, as avatars for Lung cancEr - the PADDLE study.

• IRAS ID

  224872

• Contact name

  Mary O'Brien

• Contact email

  mary.obrien@rmh.nhs.uk

• Sponsor organisation

  Royal Marsden Hospital

• Duration of Study in the UK

  3 years, 0 months, 0 days

• Research summary

  Lung cancer is the highest cause of cancer-related mortality worldwide. Research is often hampered by lack of tissue representative of a patient's cancer. In an era of precision medicine, and expanding knowledge of cancer at a genetic - DNA level, we realise there are many subgroups of lung cancer.
  Scientists have been trying to make models of cancer in mice for many years. To be able to grow the tissue in a mouse, and to get repeated biopsies from the mouse tumour, would give us a much larger quantity of tumour tissue for research than previously, and could help us improve our knowledge of lung cancer. In addition doing drug trials in mice with tumours that have come from humans could be a faster and more efficient way of developing new drug treatments for lung cancer in general, and in some cases could personalize the treatment for an individual patient. Drug trials in mice with human tumours would minimise the number of patients exposed to a futile treatment.

  These mice models are now referred to as ‘patient derived xenografts (PDXs) or avatars. Many companies can provide this service commercially as can some academic laboratories. Champions is one such US commercial company who have their laboratories in London and the US. We have made contact with them and assessed the work they have done to date and would like to explore the development of PDX models for our patients with lung cancer so that we can do mice and human drug trials in parallel.
  The first step in this process is to test the feasibility of taking biopsies from our lung cancer patients and sending them to the Champions laboratory. We will document the degree of success in the establishment of the PDX models in a number of subgroups of lung cancer.

• REC name

  London - Surrey Research Ethics Committee

• REC reference

  17/LO/1513

• Date of REC Opinion

  14 Nov 2017

• REC opinion

  Further Information Favourable Opinion